2. Search Result
Search Result
Isoforms Recommended: PKD2
Results for "

PKD2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Recombinant Proteins

2

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118052
    BPKDi

    		PKD Cardiovascular Disease
    BPKDi is a potent bipyridyl PKD inhibitor with IC50s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes .
    BPKDi
  • HY-12239
    CID755673
    Maximum Cited Publications
    7 Publications Verification

    		 PKD Cancer
    CID755673 is a potent PKD inhibitor with IC50s of 182 nM, 280 nM and 227 nM for PKD1, PKD2 and PKD3, respectively.
    CID755673
  • HY-15698A
    CRT0066101 dihydrochloride
    2 Publications Verification

    		 PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects [2] .
    CRT0066101 dihydrochloride
  • HY-15698
    CRT0066101
    2 Publications Verification

    		 PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects [2] .
    CRT0066101
  • HY-151374
    3-IN-PP1

    		PKD Cancer
    3-IN-PP1 is a protein kinase D (PKD) inhibitor. 3-IN-PP1 has potent pan-PKD inhibitory activity for PKD1, PKD2 and PKD3 with IC50 values of 108, 94 and 108 nM, respectively. 3-IN-PP1 also is a broad spectrum anticancer agent and has inhibition of several tumor cells growth. 3-IN-PP1 can be used for the research of cancer .
    3-IN-PP1
  • HY-RS10591
    PKD2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PKD2 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PKD2 Human Pre-designed siRNA Set A
    PKD2 Human Pre-designed siRNA Set A
  • HY-RS10592
    Pkd2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Pkd2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pkd2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pkd2 Mouse Pre-designed siRNA Set A
    Pkd2 Mouse Pre-designed siRNA Set A
  • HY-RS10593
    Pkd2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Pkd2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pkd2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pkd2 Rat Pre-designed siRNA Set A
    Pkd2 Rat Pre-designed siRNA Set A
  • HY-RS10594
    PKD2L1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PKD2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PKD2L1 Human Pre-designed siRNA Set A
    PKD2L1 Human Pre-designed siRNA Set A
  • HY-15698B
    CRT0066101 trihydrochloride

    		PKD Pim Apoptosis Inflammation/Immunology Cancer
    CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC50 of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects [2] .
    CRT0066101 trihydrochloride
  • HY-15528
    kb NB 142-70

    		PKD Cancer
    kb NB 142-70 is a potent PKD inhibitor, with IC50s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.
    kb NB 142-70
  • HY-112547
    CRT5

    CRT0066051

    		 PKD Others
    CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .
    CRT5
  • HY-13454
    CID 2011756

    		PKD Cancer
    CID 2011756 is an ATP competitive PKD inhibitor, with an IC50 of 3.2 μM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC50, 0.6 and 0.7 μM, respectively). CID 2011756 also has antitumor activity.
    CID 2011756
  • HY-117051
    STA-2842

    		Others Cancer
    STA-2842 is a small molecule agent that inhibits heat shock protein 90 (HSP90) to treat autosomal dominant polycystic kidney disease (ADPKD). The disease is caused by inherited mutations in the PKD1 or PKD2 genes that aberrantly activate multiple signaling proteins and pathways that regulate cell proliferation. Through network construction, we found that many HSP90 client proteins associated with ADPKD are regulated by HSP90. STA-2842 induced degradation of these clients in Pkd1?/? primary kidney cells and in vivo. In experiments using conditional Cre-mediated in vivo knockout of Pkd1 in mice, we found that weekly administration of STA-2842 for 10 weeks significantly reduced initial renal cyst formation and kidney growth in mice and slowed disease progression in mice with pre-existing cysts. These improved disease phenotypes were accompanied by improvements in renal function markers and reductions in the expression and activity of HSP90 clients and their effectors, with the extent of this inhibition correlating with the extent of cyst expansion in individual animals. Pharmacokinetic analysis showed that HSP90 was overexpressed in cystic kidney tissue and HSP90 inhibitors were selectively retained in cystic tissue, which is similar to the situation in solid tumors. These results provide a preliminary basis for evaluating HSP90 inhibitors as therapeutic agents for ADPKD.
    STA-2842

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: